Summary
- Current Price
- As of today, CRL price is $291.45, up +0.50% on
- Current Price All-Time High
- CRL price is currently -36.67% below its historical high of $460.21 set on
- Market Cap
- CRL current market cap is $14B, up +84.60% over the past 365 days
- Revenue
- CRL current annual revenue is $4.02B, down -0.85% year-over-year
- Next Earnings
- The next earnings release for CRL is on
Profile
| Metric | Value |
|---|---|
| Full Name | Charles River Laboratories Inte |
| Ticker | NYSE: CRL |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Country | United States |
| IPO | |
| Indexes | |
| Website | criver.com |
| Employees | 18,300 |
Key Metrics
| Metric | Value | Date |
|---|---|---|
| Price | $291.45 | |
| Price, 1D Change | +0.50% | |
| Market Cap | $14B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.26 | |
| Revenue | $4.02B | |
| Revenue, 1Y Change | -0.85% | |
| EPS | -$2.91 | |
| EPS, 1Y Change | -1,560.48% |
Chart
SUGGESTED SERIES
Events
| Metric | Value | Date |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Value | Date |
|---|---|---|
| EPS | -$2.91 | |
| EPS Estimate | $11.32 | N/A |
| EPS Est. Change | +488.63% | N/A |
| Revenue | $4.02B | |
| Revenue Estimate | $3.91B | N/A |
| Revenue Est. Change | -2.60% | N/A |
| Current Price | $291.45 | |
| Price Target | $300.00 | - |
| Price Tgt. Change | +2.93% | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $10.18 | $0.20 | -98.04% | |
| $10.24 | -$2.91 | -128.44% | |
| $11.32 | N/A | +488.63% | |
| $12.69 | N/A | +535.61% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $4.03B | $4.05B | +0.47% | |
| $4.01B | $4.02B | +0.23% | |
| $3.91B | N/A | -2.60% | |
| $4.00B | N/A | -0.36% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Value | Date |
|---|---|---|
| Price, 1Y | +88.59% | |
| Price, 3Y | +45.06% | |
| Market Cap, 1Y | +84.60% | |
| Market Cap, 3Y | +36.30% | |
| Revenue, 1Y | -0.85% | |
| Revenue, 3Y | +0.99% | |
| EPS, 1Y | -1,560.48% | |
| EPS, 3Y | -130.73% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Value | Date |
|---|---|---|
| Current Price | $291.45 | |
| SMA 200 | $193.44 | |
| SMA 50 | $231.96 | |
| EMA 200 | $198.87 | |
| EMA 50 | $237.93 | |
| MACD | $17.68 | |
| Beta | 1.26 | |
| ATR | $10.95 | |
| 14-Day RSI | 74.98 | |
| 10-Day Volatility | 32.17% |
Dividends
| Metric | Value | Date |
|---|---|---|
| - | N/A | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Value | Date |
|---|---|---|
| Revenue | $4.02B | |
| EPS | -$2.91 | |
| Gross Profit | $1.14B | |
| Gross Margin | 28.50% | |
| Operating Income | $401.14M | |
| Operating Margin | 9.99% | |
| Net Income | -$142.16M | |
| Net Margin | -3.54% | |
| EBITDA | $804.45M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Value | Date |
|---|---|---|
| Debt To Equity | 0.83 | |
| 1.29 | ||
| 1.02 | ||
| - | ||
| 4 | ||
| 3.22 |
Valuations
| Metric | Value | Date |
|---|---|---|
| PE Ratio | - | |
| 3.51 | ||
| 4.94 | ||
| 20.11 | ||
| - | N/A |
Balance Sheet
| Metric | Value | Date |
|---|---|---|
| Book Value | $3.16B | |
| $214.44M | ||
| $7.14B | ||
| $1.45B | ||
| $3.92B | ||
| $1.12B | ||
| Total Debt | $2.63B | |
| $61.06M | ||
| $148.80M |
Expenses
| Metric | Value | Date |
|---|---|---|
| $4.16B | ||
| $743.07M | ||
| $2.87B | ||
| $0.00 | ||
| $403.31M | ||
| $0.00 | ||
| $42.66M |
Cash Flow
| Metric | Value | Date |
|---|---|---|
| $737.65M | ||
| -$209.32M | ||
| -$536.73M | ||
| Capex | $219.15M | |
| $518.49M |
Recent analyst updates
| Metric | Value | Date |
|---|---|---|
| TD Cowen | → | |
| Morgan Stanley | → | |
| RBC Capital | → | |
| JP Morgan | → | |
| Evercore ISI Group | → | |
| CLSA | → | |
| Mizuho | → | |
| Morgan Stanley | → | |
| Morgan Stanley | → | |
| CLSA | → |
Analyst sentiment
Institutional ownership
No data
Screeners with CRL
FAQ
- What is the ticker symbol for Charles River Laboratories Inte?
- The ticker symbol for Charles River Laboratories Inte is NYSE:CRL
- Does Charles River Laboratories Inte pay dividends?
- No, Charles River Laboratories Inte does not pay dividends
- What sector is Charles River Laboratories Inte in?
- Charles River Laboratories Inte is in the Healthcare sector
- What industry is Charles River Laboratories Inte in?
- Charles River Laboratories Inte is in the Diagnostics & Research industry
- What country is Charles River Laboratories Inte based in?
- Charles River Laboratories Inte is headquartered in United States
- When did Charles River Laboratories Inte go public?
- Charles River Laboratories Inte initial public offering (IPO) was on June 23, 2000
- Is Charles River Laboratories Inte in the S&P 500?
- Yes, Charles River Laboratories Inte is included in the S&P 500 index
- Is Charles River Laboratories Inte in the NASDAQ 100?
- No, Charles River Laboratories Inte is not included in the NASDAQ 100 index
- Is Charles River Laboratories Inte in the Dow Jones?
- No, Charles River Laboratories Inte is not included in the Dow Jones index
- When was Charles River Laboratories Inte last earnings report?
- Charles River Laboratories Inte's most recent earnings report was on August 5, 2026
- When does Charles River Laboratories Inte report earnings?
- The next expected earnings date for Charles River Laboratories Inte is November 4, 2026
Data Sources & References
- CRL Official Website www.criver.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1100682/000110068226000022/0001100682-26-000022-index.htm
- List of S&P 500 Companies www.spglobal.com/spdji/en/indices/equity/sp-500/#overview
- CRL Profile on Yahoo Finance finance.yahoo.com/quote/CRL
- CRL Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/crl